Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and
in combination with anti-PD1) vs investigator choice (including clinical trials of
investigational agents, salvage therapy per local standard of care (SoC), best supportive
care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma